Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR052873)
Received: 7 February 2020
Accepted: 24 August 2020
First Online: 10 September 2020
Ethics approval and consent to participate
: The current study was performed in accordance with the ethical standards of the Helsinki Declaration, and studies (#i9018 and i12–03682) were approved by the Institutional Review Board (IRB) of NYU School of Medicine. All patients provided written, informed consent to participate in the study.
: Not applicable.
: Drs. Abramson and Attur have patent application (Patent number: 9804175) for the use of inflammatory gene expression biomarkers to identifying patients at risk for knee OA progression.